Atea Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing its financial position, share count, and ongoing clinical development activities as of that date.

Key Highlights

  • Share count: As of August 10, 2026, Atea Pharmaceuticals had 80,204,699 shares of common stock, $0.001 par value per share, outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Lead program: The company is conducting C-FORWARD, a Phase 3 clinical trial evaluating the fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV).
  • Second program: The company disclosed clinical trials evaluating AT-587, a product candidate for the treatment of hepatitis E virus (HEV).
  • Regulatory milestone: The company referenced anticipated submission of a new drug application to the U.S. Food and Drug Administration seeking approval to market the BEM/RZR regimen for HCV treatment in the United States.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Atea Pharmaceuticals Q2 2026: Clinical Pipeline and Corporate Status

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), headquartered at 225 Franklin Street, Suite 2100, Boston, MA 02110, filed its Form 10-Q for the quarterly period ended June 30, 2026. The filing confirms the company held 80,204,699 shares of common stock outstanding as of August 10, 2026, with a par value of $0.001 per share. The company's common stock is listed on The Nasdaq Global Select Market under the trading symbol AVIR.

According to the filing, the company's primary development activities center on two antiviral programs. The lead program involves BEM/RZR, a fixed-dose combination of bemnifosbuvir and ruzasvir, currently being evaluated in a Phase 3 clinical trial called C-FORWARD for the treatment of HCV. The company also disclosed that it is conducting clinical trials of AT-587, a product candidate for HEV treatment. The filing referenced forward-looking statements regarding anticipated submission of a new drug application to the FDA for the BEM/RZR HCV regimen, noting these statements involve risks and uncertainties and are subject to the cautionary language included in the report.

The filing identifies the company as a non-accelerated filer and smaller reporting company, and confirms it is not an emerging growth company. The company's forward-looking statements, as the filing describes, cover topics including clinical trial timelines and costs, regulatory submissions, market opportunities, manufacturing strategy, capital requirements, and cash runway. The filing states these statements "involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different" from those expressed or implied, and directs readers to the Risk Factors section of the report for additional detail.

What Was Disclosed

Atea Pharmaceuticals filed its June 30, 2026 quarterly report disclosing 80,204,699 shares outstanding, its Phase 3 HCV trial (C-FORWARD) and HEV candidate (AT-587), anticipated FDA NDA submission for BEM/RZR, and its smaller reporting company classification.